文章摘要

文章信息/Info

Title:: Clinical research progress in novel biomarkers of heart failure

作者:: 李宏丽¹; 王小艳²; 石卉³ 综述; 张瑞英¹ 审校; (1.哈尔滨医科大学附属第一医院心内科, 黑龙江哈尔滨 150001；
2.绥化市人民医院心内科，黑龙江绥化 152000；
3.黑龙江省医院老年诊室，黑龙江哈尔滨 150001)

Author(s):: LI Hong-li¹; WANG Xiao-yan²; SHI Hui³; ZHANG Rui-ying¹; (1.Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China;
2.Department of Cardiology, Suihua Peoples Hospital, Suihua 152000, Heilongjiang, China;
3.Geriatric Clinic, Heilongjiang Province Hospital, Harbin 150001, Heilongjiang, China)

关键词:: 心力衰竭; ST2; 半乳糖凝集素-3; 半胱氨酸蛋白酶抑制剂C

Keywords:: Heart failure; ST2; galectin-3; cystatin C

分类号:: R541.6

DOI:: -

文献标识码:: A

摘要:: 心力衰竭（HF）的发生发展涉及复杂的病理生理学机制间的相互作用，包括炎症，组织重构，神经激素和内分泌，以及肾脏和交感神经等。随着对HF机制探索的不断深入，人们对HF的生物标记物的认识也更趋全面。本文简要介绍一些在此过程中发现的新的生物标记物，如ST2，半乳糖凝集素-3,半胱氨酸蛋白酶抑制剂C等，并对其临床价值做一综述。

Abstract:: The development of heart failure (HF) involves an interplay of multiple pathophysiological mechanisms including inflammation, tissue remodeling, neurohormonal and endocrine signaling, and interactions with the renal and nervous systems. Understanding of the biomarkers in HF is more comprehensive now as a result of the furthering of the exploration of the HF mechanism. In this paper we will briefly review some new biomarkers such as ST2, galectin-3 and cystatin C and their clinical values.

参考文献/References

[1]Gullestad L,Ueland T,Kjekshus J,et al.Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)［J］. Eur Heart J, 2012 ,33(18):2290-2296.
[2]O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure［J］. N Engl J Med, 2011, 365(1):32-43.
[3]Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1［J］. Proc Natl Acad Sci USA, 2009, 106(22):9021-9026.
[4]Zhang HF, Xie SL, Chen YX, et al. Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress［J］. J Transl Med, 2012, 10:120.
[5]Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure［J］. Eur J Heart Fail, 2011, 13(7):718-725.
[6]Broch K, Ueland T, Nymo SH, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology［J］. Eur J Heart Fail, 2012, 14(3):268-277.
[7]Bayes-Genis A, de Antonio M, Galan A, et al. Combined use of high-sensitivity ST2 and NT-proBNP to improve the prediction of death in heart failure［J］. Eur J Heart Fail, 2012, 14(1):32-38.
[8]Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure［J］. J Card Fail, 2008, 14(9):732-738.
[9]Aldous SJ, Richards AM, Troughton R, et al. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain［J］. J Card Fail, 2012, 18(4):304-310.
[10]van der Velde AR, Gullestad L, Ueland T, et al. Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure Data From CORONA and COACH［J］. Circ Heart Fail, 2013, 6(2):219-226.
[11]de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value o plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction［J］. Ann Med, 2011, 43(1):60-68.
[12]Sherwi N, Merali S, Wong K.Personalizing biomarker strategies in heart failure with galectin-3［J］. Future Cardiol, 2012, 8(6):885-894.
[13]Laurent C, Maria M, Pascal R, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis［J］. Arte-rioscler Thromb Vasc Biol, 2013, 33(1):67-75.
[14]Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure［J］. Eur Heart J, 2012, 33(17):2135-2142.
[15]Cleland JG, Carubelli V, Castiello T, et al. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis［J］. Heart Fail Rev, 2012, 17(2):133-149.
[16]Damman K, Voors AA, Navis G, et al. Current and novel renal biomarkers in heart failure［J］. Heart Fail Rev, 2012, 17(2):241-250.
[17]Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure［J］. J Card Fail, 2010, 16(1):49-54.
[18]Damman K, Masson S, Hillege HL, et al. Clinical outcome of renal tubular damage in chronic heart failure［J］. Eur Heart J, 2011, 32(21):2705-2712.
[19]Alvelos M, Lourenco P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure［J］. Int J Cardiol, 2013, 165(1):51-55.
[20]Potocki M, Breidthardt T, Reichlin T, et al. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study［J］. Crit Care, 2009, 13(4):R122.
[21]Adlbrecht C, Hulsmann M, Strunk G, et al. Prognostic value of plasma midregional proadrenomedullin and C-terminal-pro-endo-thelin-1 in chronic heart failure outpatients［J］. Eur J Heart Fail, 2009, 11(4):361-366.
[22]Maisel A, Mueller C, Nowak R, et al. Mid-region prohormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart failure) trial［J］. J Am Coll Cardiol, 2010, 55(19):2062-2076.
[23]Gupta S, Drazner M, de Lemos J. Newer biomarkers in heart failure［J］. Heart Fail Clin, 2009, 5(4):579-588.
[24]Dieplinger B, Gegenhuber A, Struck J, et al. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure［J］. Clin Chim Acta, 2009, 400(1-2):91-96.
[25]Jansson A, Rsj H, Omland T. Prognostic value of circulating chromogranin A levels in acute coronary syndromes［J］. Eur Heart J, 2009, 30(1):25-32.
[26]Dieplinger B, Gegenhuber A, Kaar G, et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department［J］. Clin Biochem, 2010, 43(9):714-719.
[27]McGaffin K, Witham W, Yester K, et al. Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice［J］. Cardiovasc Res, 2011, 89(1):60-71.
[28]LiebW, Sullivan L, Harris T, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals［J］. Diabetes Care, 2009, 32(4):612-616.

我们的网站为什么显示成这样？

心力衰竭新标记物临床研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics